

Optum Rx Report: Notable New Drugs™

Fall 2024 Summary



Hympavzi™ (marstacimab-hncq) **FDA approved Oct. 11, 2024**

Hympavzi has been approved to prevent or reduce the frequency of hemophilia bleeding episodes. Hympavzi offers a first-in-class treatment option for both hemophilia A and B. It will provide new competition for Hemlibra® (emicizumab-kxwh) for hemophilia A.

Hympavzi continues the trend toward more effective treatments for hemophilia, resulting in increasing life spans for patients. In studies annualized bleeding rates were reduced by 35% vs. routine prophylaxis and by nearly 92% vs. on-demand therapy.

The annual wholesale acquisition cost (WAC) for Hympavzi will be \$795,600.



Itovebi™ (inavolisib) **FDA approved: Oct. 10, 2024**

Itovebi is a new first-line option for people with HR-positive breast cancer with a PIK3CA mutation. The approval stipulates Itovebi will be used in combination with Ibrance® (palbociclib) and fulvestrant.

In a clinical study, patients who added Itovebi to the standard care regimen experienced a 57% reduction in the risk of worsening disease or death than those who only received standard care. Based on these outcomes, the new 3-way combination could become a first-line standard of care.

The Wholesale Acquisition Cost (WAC) for Itovebi is \$274,400 per year. The WAC for a competitor, Piqray® (alpelisib), is approximately \$287,000 per year.



Acoramidis

Expected FDA decision: Nov. 29, 2024

Acoramidis is intended to treat cardiomyopathy associated with transthyretin amyloidosis (ATTR-CM). This is a genetic condition that causes the heart to stiffen and lose pumping capacity. Life expectancy is reduced by 2–6 years from diagnosis.

Acoramidis is a potential competitor to Pfizer's Vyndamax® (tafamidis). Vyndamax earned Pfizer \$3.3B in 2023 sales – up more than 35% from 2022.

Study results show that at month 30, the survival rate was 81% with acoramidis vs. 74% with placebo. This represents a 25% relative reduction in death risk.

Estimated cost: Prices not yet released. The Wholesale Acquisition Cost for Vyndamax is approximately \$270,000 per year.